• UCB flagged new three-year data on BIMZELX for moderate-to-severe hidradenitis suppurativa, presented at EADV 2026.
• Analyses indicated earlier use improved the likelihood of full inflammatory lesion clearance versus later treatment.
• Results also showed stronger tunnel resolution in biologic-naive patients than in those previously treated with biologics.
• One-year findings suggested the drug reduced overall tunnel burden, supporting a potential effect on longer-term disease progression.
• Safety over three years remained consistent with earlier experience, with no new safety signals reported.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. UCB SA published the original content used to generate this news brief on September 30, 2026, and is solely responsible for the information contained therein.